Gladio

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gladio

What is Gladio? (Aceclofenac)

Property Description
Active ingredient Aceclofenac
Form Tablets (film-coated), Powder, Cream
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use Relief of pain and inflammation
Origin Synthetic, Acetic acid derivative

What Type of Medication is Gladio?

Gladio is a pharmaceutical preparation whose active ingredient is Aceclofenac, which is officially categorized as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This classification places it within the general group of medicines known for providing relief from pain and inflammation. Aceclofenac is a synthetic, single-ingredient compound that is chemically defined as an acetic acid derivative, a sub-class structurally related to Diclofenac. This identity confirms its function in managing symptoms arising from inflammatory and painful processes, as listed in the ATC classification system.

Composition, Forms, and General Therapeutic Purpose

The fundamental composition of Gladio is based solely on the active substance, Aceclofenac, combined with necessary carriers for delivery. It is characteristically supplied in multiple dosage forms, including film-coated tablets for systemic use, and a cream for localized, topical application. The general therapeutic purpose is to provide simultaneous analgesic (pain-relieving) and anti-inflammatory effects, which are the dual benefits inherent to its chemical class. Clinical literature supports the efficacy of Aceclofenac as an effective agent for managing discomfort associated with conditions like joint stiffness or muscle strain.

How Does Gladio Relieve Pain and Inflammation? (High-Level Function)

Gladio's anti-inflammatory function is rooted in its ability to intervene directly in the body's processes that cause pain and swelling. The mechanism involves inhibiting the Cyclooxygenase (COX) enzyme, a crucial step in the biological pathway responsible for synthesizing inflammatory chemicals called prostaglandins. By reducing the production of these key mediators, the medicine lessens the intensity of pain signals and diminishes the physiological signs of inflammation, such as swelling and warmth, thereby providing reliable symptomatic relief.

What side effects are possible with Gladio?

Possible Side Effects and Safety Information

Gladio is associated with a risk of serious and potentially irreversible adverse reactions, which has led the U.S. Food and Drug Administration (FDA) to require a Boxed Warning on the product labeling. This is the strictest safety warning for prescription drugs.

Serious and Clinically Significant Adverse Reactions

The most serious documented adverse reactions involve multiple body systems and can be permanent. These include:

  • Musculoskeletal and Connective Tissue Disorders: Tendinitis and tendon rupture (especially of the Achilles tendon), muscle pain, muscle weakness, and joint pain or swelling.
  • Nervous System Effects: Peripheral neuropathy (nerve damage causing numbness, tingling, or burning sensation in the limbs) and serious Central Nervous System (CNS) effects such as anxiety, confusion, hallucinations, depression, and suicidal thoughts.
  • Cardiovascular Risks: Abnormal or irregular heart beat, prolongation of the QT interval, and an increased risk of aortic aneurysm and dissection.
  • Other Serious Events: Severe diarrhea (potentially Clostridium difficile-associated diarrhea), serious hypersensitivity reactions (including anaphylaxis), and exacerbation of myasthenia gravis.

Common Side Effects

Commonly reported side effects often involve the gastrointestinal and nervous systems. These may include nausea, diarrhea, headache, dizziness, and difficulty sleeping.

Safety Restrictions and Monitoring

The FDA requires that the use of systemic Gladio be restricted for certain uncomplicated bacterial infections (acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated urinary tract infections) when alternative treatment options are available, as the risks are considered to outweigh the benefits in these situations. Due to the rapid onset of some severe side effects, treatment should be stopped immediately if a patient reports symptoms of peripheral neuropathy (e.g., tingling) or any serious CNS event, and an alternative drug should be considered.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section outlines the official descriptions of overdose and mandated emergency actions based on authoritative government regulatory documents.

Overdose Scope

Domain Official Regulatory Statement
Documented Overdose Presentations Non-specific symptoms may include Nausea, Vomiting, Pain abdomen, Dizziness, Somnolence, Headache, and Sweating.
Physiological Systems Affected Overdose carries the risk of Acute renal failure, Hepatic failure/Liver damage, Pancreatitis, and serious Cardiovascular thrombotic events (Heart attack, Stroke).
Emergency-Response Statements Seek medical attention immediately.
When Immediate Help is Required Immediate attention is required for symptoms indicative of a serious cardiovascular event, such as Chest pain, Shortness of breath, Sudden weakness or numbness, or Sudden slurred speech.

Overdose Classifications (High-Level)

Classification Aspect Official Regulatory Statement
Severity Classification Overdose may lead to severe or fatal consequences.
Regulatory Basis Information derived from Aceclofenac Summary of Product Characteristics (SmPC) and U.S. Food and Drug Administration (FDA)-mandated class warnings.

Resulting Overdose Structure

Official overdose statements:

  • Antidote Status: There is no specific antidote known for acute Aceclofenac toxicity.
  • Supportive Procedures: Treatment involves symptomatic and supportive measures, including consideration for Gastric lavage and the administration of Activated charcoal for potentially life-threatening doses.
  • Monitoring: Close monitoring of renal and liver function is required in cases of significant poisoning.

Connection to the overall overdose profile (regulatory summary):

Regulatory documents define the official overdose profile by listing non-specific acute symptoms alongside the explicit risk of severe organ damage and cardiovascular events. This framework strictly mandates that individuals seek immediate medical attention upon suspicion of overdose or the manifestation of specific life-threatening symptoms. Official guidance outlines management focused on symptomatic support, decontamination, and close monitoring.

Therapeutic Uses of Gladio

What Gladio Treats: Main Uses and Benefits

Gladio, with the active substance diclofenac, belongs to the group of medicines classified as non-steroidal anti-inflammatory drugs (NSAIDs). It is applied across domains where additional symptomatic support is needed and is relevant in contexts marked by increased discomfort or tension. It generally contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

The primary therapeutic domain for this medicine is the relief of signs and symptoms associated with conditions involving episodic or fluctuating manifestations. Diclofenac is commonly used to help with the management of conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

The medicine is also relevant for easing acute or disruptive episodes. It is applied in clinical settings that involve acute or unstable symptom patterns, or when short-term symptomatic assistance is needed for symptoms of increased neurological or muscular activity.

“This supportive relief may assist with maintaining functional stability and helps maintain a sense of stability when symptoms are more noticeable.”

This medicine is considered relevant in contexts where patients experience symptoms related to physical discomfort that interfere with daily comfort.

Quick Fact: Relevant for Managing Symptoms that Create Noticeable Physiological Strain

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Authoritative governmental regulatory documents from agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) do not contain official prescribing information, contraindications, or eligibility statements for a pharmaceutical product named Gladio. Consequently, a definitive regulatory profile specifying who can and cannot use this medicine cannot be established based on mandatory government labeling.

Regulatory documents establish clear rules for population eligibility, including formal contraindications and restrictions, before a medicine can be marketed. In the absence of an approved label, the following official information regarding eligibility is not available:

  • Populations for whom use is contraindicated: None found.
  • Age-related eligibility rules: Specific rules for use in pediatric or geriatric populations are not documented.
  • Condition-specific eligibility rules: Official restrictions related to severe hepatic impairment, renal impairment, or other specific pre-existing medical conditions are not documented.

Without documented official approval, any use of a product under this name is outside the scope of regulated pharmaceutical eligibility.

What should I know about interactions with other medicines?

Gladio Interactions with other medicines and products

The following section outlines officially documented interaction patterns for Gladio (Aceclofenac) as defined in government regulatory information.

Interaction Type Interacting Agents / Classes Regulatory Requirement
Prohibited Co-administration Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Aspirin Must be avoided due to significantly increased risk of gastrointestinal (GI) bleeding and ulceration.
Mifepristone Use must be separated by 8 to 12 days to avoid reducing the therapeutic effect of Mifepristone.
Exposure Modification Risk Lithium, Digoxin, Methotrexate Aceclofenac may decrease the elimination of these medicines, leading to increased plasma concentrations and a potential for toxicity, requiring monitoring.
Pharmacodynamic Risk Anti-coagulants (e.g., Warfarin), Systemic Corticosteroids, SSRIs Co-administration may enhance the risk of bleeding or GI ulceration, necessitating close patient monitoring.
Anti-hypertensives (e.g., ACE inhibitors, ARBs) Reduced anti-hypertensive effect and an increased, officially documented risk of acute renal insufficiency.
Diuretics, Ciclosporin, Tacrolimus Increased risk of nephrotoxicity and reduced diuretic effect.
Substance Interaction Alcohol (Ethanol) Avoidance is required as it increases the risk of gastric irritation and GI bleeding.

This interaction profile necessitates constraints on co-administration to manage officially documented risks. Elderly patients and those with compromised renal function are noted in regulatory information as having a heightened susceptibility to interactions affecting kidney function. Caution is required when combining Aceclofenac with Methotrexate, specifically if administered within 24 hours of each other.

Mechanism of Action

How Gladio Works

Gladio’s mechanism is centered on the competitive inhibition of the Cyclooxygenase (COX) enzymes, primarily targeting the inducible COX-2 form with greater affinity than the constitutive COX-1 form. By blocking COX-2, the drug restricts the enzymatic synthesis of prostaglandins, which are essential chemical messengers that initiate and amplify localized physiological responses to tissue changes. The suppression of prostaglandin synthesis is central to the drug’s action.

This reduction in mediators at the tissue level directly decreases the sensitivity threshold of peripheral nociceptors (sensory nerve endings). This physiological adjustment modulates the transmission of afferent signaling from the periphery, influencing activity within nociceptive pathways. The drug’s interaction profile also involves COX-1, the enzyme regulating basal functions such as gastric mucosal integrity and renal blood flow regulation. This breadth of functional interaction influences system-level consequences related to vascular tone and fluid balance regulation.

Dosage and Administration Information

The administration of Gladio, which contains Aceclofenac, is defined by established parameters concerning dose, frequency, and preparation. This medicine is approved for systemic use via the oral route (film-coated tablets or powder) and for localized application via the topical route (cream). For oral intake, the standard adult regimen is established at 100 mg per dose, typically administered twice daily (morning and evening). The maximum total daily dose documented in prescribing information is 200 mg. Patients using the extended-release oral formulation typically follow a once-daily schedule for the 200 mg dose.

Official instructions specify that oral tablets must be swallowed whole with liquid and are not to be crushed or chewed to preserve the intended release characteristics. Administration may occur with or after food, as the rate of absorption is affected but not the overall quantity of the substance absorbed by the body. The general principle guiding its use over time requires the adoption of the lowest effective dose for the shortest duration necessary to manage symptoms.

Dose adjustments are specified for certain populations. For patients with hepatic impairment, the initial daily dose should be reduced to 100 mg. No specific modification to the dose or frequency is generally required for older adults or those with mild renal impairment. The use of Aceclofenac in the pediatric population is not recommended due to a lack of clinical data in this group. If a dose is missed, instructions advise the user to simply skip the missed dose and take the next one at the usual time; doubling the dose is not permitted.

Recent Clinical Evidence

Gladio: Recent Clinical Evidence

Evidence from Studies for Osteoarthritis and Rheumatoid Arthritis

Research on Gladio (Aceclofenac) for osteoarthritis (OA) and rheumatoid arthritis (RA) relies primarily on short-term, randomized controlled trials (RCTs). These studies involved adult populations and examined outcomes monitoring physiological strain or stress, along with outcomes reflecting daily functioning or activity level, using standardized tools like the WOMAC Index. For RA, research also monitored changes in disease activity scores, such as the ACR criteria and the duration of morning stiffness. Studies explored how symptoms evolved in the observed populations during the trial periods, with findings describing patterns observed related to perceived discomfort and mobility.

Evidence from Studies for Ankylosing Spondylitis

Gladio was studied for use in ankylosing spondylitis, focusing on changes in pain intensity and spinal mobility. While trials reported that these outcomes were monitored, the overall research pool is generally described as having sample sizes that were modest. Consequently, the evidence quality varies across studies for this specific condition, and the results apply only to the populations studied.

Long-Term Follow-up and Research Gaps

Most foundational evidence is derived from short-term trials where follow-up durations were limited, typically lasting only a few weeks to three months. Long-term effects are not fully established regarding sustained status or functional durability over many months or years. The research focuses primarily on symptomatic patterns, and there is limited information regarding the influence on the progression of the underlying disease or structural joint damage. Furthermore, data for certain groups remain insufficient, including dedicated trials examining specific effects in older adults subgroups. This high degree of uncertainty must be noted when reviewing the evidence landscape.

Key Studies & References

  1. A Review of Aceclofenac: Analgesic and Anti-Inflammatory Effects on Musculoskeletal Disorders
  2. Efficacy and safety of aceclofenac in osteoarthritis: A meta-analysis of randomized controlled trials
  3. Public Assessment Report for Aceclofenac 100 mg film-coated Tablets (UK/EU Decentralised Procedure)

Frequently Asked Questions (FAQ)

Common questions about Gladio (FAQ)

Q: How quickly should I expect Gladio tablets to start working for pain relief?

A: Official regulatory documents indicate that the maximum concentration of the drug in the bloodstream is generally reached about one to three hours after taking an oral tablet dose. This timing reflects when the medicine's concentration is typically at its highest level.


Q: What is the difference between Gladio tablets and the Gladio cream or gel formulation?

A: The tablets are approved for systemic treatment, meaning they work throughout the body to relieve general pain and inflammation. In contrast, the cream or gel formulation is designed only for localized, topical application directly onto the affected area of the skin.


Q: Is Gladio safe for use in older patients or the elderly?

A: Regulatory information advises caution for older patients because they have an increased risk of specific adverse reactions to NSAIDs, such as serious bleeding in the stomach or issues with kidney function. Official information highlights that medical supervision may be warranted for older adults.


Q: How long can a person safely take Gladio without a break?

A: Regulatory guidelines emphasize that side effects can be minimized by utilizing the lowest effective dose for the shortest duration necessary to control symptoms. The product information stresses that treatment should be limited to the time needed for symptom relief.


Q: Are there any specific warnings for individuals with heart conditions taking Gladio?

A: Official information indicates the drug is contraindicated, meaning its use is restricted, in patients with established heart conditions such as advanced congestive heart failure, ischemic heart disease, or recent stroke. Individuals with a history of high blood pressure or milder heart failure require careful medical monitoring during use.


Q: If I am taking a diuretic, will Gladio have a different effect on me?

A: Co-administering Gladio with diuretic medicines may reduce the intended water-shedding effect of the diuretic. Furthermore, this combination carries an increased official risk of nephrotoxicity, which is potential harm to the kidneys, meaning monitoring is essential.


Q: Why do some people use Gladio for conditions other than arthritis?

A: While Gladio is known for treating different types of arthritis, official indications in various countries also include the treatment of other painful and inflammatory conditions. These may include dental pain, pain following surgery, and the relief of menstrual pain (dysmenorrhea).


Q: Can Gladio be used for period pain or gynecological inflammation?

A: In certain regulatory jurisdictions, this medication is formally indicated for the treatment of pain associated with menstruation, known as dysmenorrhea.


Q: Is it normal to feel a bit dizzy or nauseous after starting Gladio?

A: Regulatory documents list both dizziness and nausea as common side effects of this medication. Common side effects are those that have been frequently reported by patients during clinical studies.


Q: Can Gladio affect liver enzyme levels, and how would I know?

A: Official information indicates that elevations of liver enzymes in the blood have been reported as a common side effect. If abnormal liver function test results persist or worsen, discontinuation of the medication may be considered by a healthcare professional.


Q: Can Gladio cause increased sensitivity to sunlight?

A: Although it is not a common side effect, some regulatory documents mention a risk of photosensitivity, which is a skin reaction to sunlight, associated with this class of NSAID drugs.


Q: Is it possible to become dependent on Gladio with long-term use?

A: Regulatory information and product labeling do not report that Gladio has habit-forming properties or that dependence is a recognized risk with long-term use.


Q: How does Gladio affect people who have asthma or allergies to other pain medicines?

A: Gladio is contraindicated for people who experience attacks of asthma, acute nasal inflammation, or hives when taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs). Its use may trigger or worsen these conditions in susceptible individuals.


Q: Can Gladio be used for pain after a dental procedure or surgery?

A: Yes, the drug is officially indicated in certain regions for managing both dental pain and pain that occurs after a surgical procedure.


Q: Does Gladio affect blood sugar levels, and is it a concern for diabetics?

A: Regulatory documents mention interaction studies with oral anti-diabetic agents. Official information notes that monitoring of blood glucose levels may be required when these agents are co-administered.


Q: Can Gladio interact with herbal supplements or vitamins?

A: The specific interaction profile with all herbal supplements is not fully listed in regulatory documents. The manufacturer’s labeling recommends that patients inform their healthcare provider of all concomitant medications and supplements, given the potential for enhanced risks, such as bleeding, when combined with agents that affect clotting.


Q: Does Gladio have a sedative effect or cause drowsiness that impacts driving?

A: Undesirable effects such as dizziness, a spinning sensation (vertigo), and drowsiness may occur while taking this medication. Official warnings advise patients who experience these effects to avoid operating machinery or driving.


Q: What are the signs of an allergic reaction to Gladio that require immediate attention?

A: A severe allergic reaction (anaphylaxis) requires immediate medical attention. Official information lists signs that may include difficulty breathing, wheezing, swelling of the face or throat, or a rapid onset rash. The drug should be discontinued at the first sign of a skin rash or mucosal lesion.


Q: Is Gladio used to treat headaches or migraines?

A: Official information from certain regulatory jurisdictions indicates that the drug is approved for providing relief from headaches.


Q: Does taking Gladio affect fertility in men or women?

A: Regulatory documents advise that use of the drug may potentially impair female fertility. It is generally not recommended for women who are actively trying to conceive.


Q: Why is Gladio contraindicated in the last trimester of pregnancy?

A: The drug is contraindicated during the last three months of pregnancy because, as an NSAID, it poses a risk to the fetus. Specifically, it can cause the premature closing of the fetal ductus arteriosus, which is a critical blood vessel in the unborn child’s heart.


Q: How does Gladio's mechanism of action compare to COX-2 inhibitors?

A: The medicine's mechanism involves inhibiting the Cyclooxygenase (COX) enzymes, primarily targeting the inducible COX-2 form with greater affinity than the constitutive COX-1 form. This profile is shared by other medications in the NSAID class.


Q: Is Gladio effective for treating gout attacks?

A: In some regulatory jurisdictions, official indications include the treatment of the pain and inflammation associated with acute attacks of gout.


Q: Can Gladio cause skin rashes or other dermatological side effects?

A: Skin rash is listed in regulatory documents as a common side effect. Very rarely, serious skin reactions, including life-threatening conditions like Stevens-Johnson syndrome, have also been reported with this medication.


Q: Does Gladio work well for chronic back pain?

A: Regulatory and clinical data from some regions support the use of this drug for the management of pain and inflammation associated with chronic conditions like low back pain (LBP).


Q: What studies have been done on Gladio's long-term safety profile?

A: While the core evidence base relies on short-term trials, regulatory texts recommend that all patients receiving long-term NSAID treatment should undergo regular monitoring. This monitoring includes checks on kidney and liver function, as well as blood counts.


Q: Can Gladio be taken by someone who recently had a major surgery?

A: The drug is specifically contraindicated (should not be used) in the setting of coronary artery bypass graft (CABG) surgery. Due to increased bleeding and cardiovascular risk, its use is generally not recommended for immediate post-operative pain following other major surgeries either.


Q: Is there a maximum number of days Gladio is usually recommended for acute pain?

A: Official guidance for acute pain emphasizes the use of the lowest effective dose for the shortest time necessary. For related injectable forms, administration for more than two days is specifically advised against.


Q: Is Gladio available in forms suitable for people who have trouble swallowing tablets?

A: In addition to standard film-coated tablets, the drug is available in some regions as a powder for oral suspension or as specialized mouth-dissolving tablets. These alternative forms are intended to be suitable for patients who have difficulty swallowing pills.

How should Gladio be stored and disposed of?

Official Storage and Disposal Requirements

Gladio (Aceclofenac 100 mg Tablets) is defined by regulatory documents as a product that does not require any special storage conditions. This means the medicine is stable when kept at standard room temperature in its original packaging.

Requirement Official Regulatory Statement
Temperature Does not require any special storage conditions.
Stability Has a shelf life of 3 years when stored in the original blister.
Packaging Must be kept in the Aluminium/aluminium blisters and cardboard box.
Disposal There are no special requirements for the disposal of unused product.

To ensure product stability, always keep the medication in the original blister pack. Unused or expired tablets must be discarded according to standard local pharmaceutical waste regulations, as the labeling specifies no unique hazardous handling or disposal protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gladio found in:

A-Z Index: